Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target ...

Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, ...

Environmental Monitoring Market Size Rising demand for natural resource management, growing health concerns from pollution, & eco-friendly ...

Independent research institute BioMed X has completed its oncology research project in partnership with Merck, the data from ...

Merck Sharp & Dohme LLC has identified targeted activator of cell kill (TACK) compounds acting as Gag polyprotein (HIV-1)/protein Pol dimerization inducers reported to be useful for the treatment of ...

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.

AQILION AB (publ) announces that the Company has resumed development of the its TAK1 program as the company has regained the control and ownership of the program. After reviewing and analysing the ...